ArticleScientific reports2018
A murine model of atopic dermatitis can be generated by painting the dorsal skin with hapten twice 14 days apart.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- TMEM207-mediated the impairment of skin regeneration through YAP sequestration in an allergic contact dermatitis model.Biochemistry and biophysics reports · 2026Article
- Guilty by association: direct interaction with the tetraspanin CD63 suggests a role for organic cation transporter 3 in histamine release from granulocytes.Journal of biomedical science · 2025Article
- Effect of L-theanine in the prevention of 2,4- dinitrochlorobenzene induced atopic dermatitis: A study in BALB/c mice model.Toxicology reports · 2025Article
- Comparative study of mouse models of atopic dermatitis.Heliyon · 2025Review
- Vinpocetine, a phosphodiesterase 1 inhibitor, mitigates atopic dermatitis-like skin inflammation.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- Discovery of a Small Molecule Activator of Slack (Kcnt1) Potassium Channels That Significantly Reduces Scratching in Mouse Models of Histamine-Independent and Chronic Itch.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Preclinical Models of Atopic Dermatitis Suitable for Mechanistic and Therapeutic Investigations.Journal of inflammation research · 2024Review
- Human umbilical cord mesenchymal stem cell treatment alleviates symptoms in an atopic dermatitis-like mouse model.Stem cell research & therapy · 2023Article
- Article
- Article
- Mouse Model of Irritant Contact Dermatitis.Iranian journal of pharmaceutical research : IJPR · 2022Article
- Observation of hapten-induced sensitization responses for the development of a mouse skin sensitization test, including the elicitation phase.Scientific reports · 2022Article
- Immunomodulatory Role ofPathogens (Basel, Switzerland) · 2022Review
- Concentration optimization of combinatorial drugs using Markov chain-based models.BMC bioinformatics · 2021Article
- Translational Relevance of Mouse Models of Atopic Dermatitis.Journal of clinical medicine · 2021Review
- Suppression of DNCB-Induced Atopic Skin Lesions in Mice byNutrients · 2020Article
- Article
- Phloretin alleviates dinitrochlorobenzene-induced dermatitis in BALB/c mice.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug development involves pharmacometric experiments in animals. Such experiments should limit animal pain and stress. Conventional murine models of atopic dermatitis (AD) used in drug development are generated by weekly painting of hapten on dorsal skin for 5 weeks. The present study aimed to develop a protocol that involves less animal distress. The experiments focused on serum total IgE levels, which are a marker of AD. The conventional protocol induced ever rising IgE levels. Experiments with extended intervals between sensitizations showed that IgE peaked ~5 days after the second sensitization, after which it returned to the control level within 12-19 days. An additional third sensitization on day 28 further increased the serum IgE level. In the 4-5 days after the second sensitization, the dorsal skin exhibited typical AD-like lesions with edema, scabs, epithelial-cell hypertrophy, marked mast-cell and lymphocyte infiltration of dermis, and increased IL-4, IL-6, IL-10, IL-1β, IL-17A, IFN-γ and TNF-α expression. Thus, two 2,4-dinitrofluorobenzene sensitizations yield a murine AD model in less than 20 days. This study shows that animal model protocols used in drug development can be fine-tuned so that they remain effective yet cause animals less stress and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.